1. Home
  2. UTHR vs PAYC Comparison

UTHR vs PAYC Comparison

Compare UTHR & PAYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UTHR
  • PAYC
  • Stock Information
  • Founded
  • UTHR 1996
  • PAYC 1998
  • Country
  • UTHR United States
  • PAYC United States
  • Employees
  • UTHR N/A
  • PAYC N/A
  • Industry
  • UTHR Biotechnology: Pharmaceutical Preparations
  • PAYC Computer Software: Prepackaged Software
  • Sector
  • UTHR Health Care
  • PAYC Technology
  • Exchange
  • UTHR Nasdaq
  • PAYC Nasdaq
  • Market Cap
  • UTHR 13.8B
  • PAYC 12.8B
  • IPO Year
  • UTHR 1999
  • PAYC 2014
  • Fundamental
  • Price
  • UTHR $405.02
  • PAYC $222.77
  • Analyst Decision
  • UTHR Strong Buy
  • PAYC Hold
  • Analyst Count
  • UTHR 15
  • PAYC 11
  • Target Price
  • UTHR $449.13
  • PAYC $234.80
  • AVG Volume (30 Days)
  • UTHR 902.7K
  • PAYC 588.3K
  • Earning Date
  • UTHR 10-29-2025
  • PAYC 10-29-2025
  • Dividend Yield
  • UTHR N/A
  • PAYC 0.67%
  • EPS Growth
  • UTHR 17.94
  • PAYC N/A
  • EPS
  • UTHR 25.63
  • PAYC 7.40
  • Revenue
  • UTHR $3,077,800,000.00
  • PAYC $1,959,900,000.00
  • Revenue This Year
  • UTHR $13.89
  • PAYC $11.03
  • Revenue Next Year
  • UTHR $5.68
  • PAYC $9.09
  • P/E Ratio
  • UTHR $15.80
  • PAYC $30.08
  • Revenue Growth
  • UTHR 17.62
  • PAYC 10.21
  • 52 Week Low
  • UTHR $266.98
  • PAYC $158.03
  • 52 Week High
  • UTHR $436.95
  • PAYC $267.76
  • Technical
  • Relative Strength Index (RSI)
  • UTHR 71.35
  • PAYC 46.85
  • Support Level
  • UTHR $395.00
  • PAYC $219.22
  • Resistance Level
  • UTHR $401.62
  • PAYC $227.49
  • Average True Range (ATR)
  • UTHR 13.35
  • PAYC 4.70
  • MACD
  • UTHR 6.12
  • PAYC 0.07
  • Stochastic Oscillator
  • UTHR 76.31
  • PAYC 35.65

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

About PAYC Paycom Software Inc.

Founded in 1998, Paycom is a human capital management software-as-a-service provider addressing customer requirements surrounding payroll, talent acquisition, talent management, HR management, as well as time and labor. The company primarily services midsize businesses within the United States, targeting businesses with 50-10,000 employees. The company primarily generates revenue through the sale of subscriptions providing access to its HCM platform. To a lesser extent, the company also generates revenue from implementation services provided to customers as well as interest income generated from customer funds. As of fiscal 2024, the company serviced slightly over 37,500 customers and stored data on over 7 million employees.

Share on Social Networks: